K. H. Yeung, P. Duclos, E. A. Nelson, and R. C. Hutubessy, An update of the global burden of pertussis in children younger than 5 years: a modelling study, Lancet Infect. Dis, vol.17, pp.974-980, 2017.

N. S. Crowcroft, N. Andrews, C. Rooney, M. Brisson, and E. Miller, Deaths from pertussis are underestimated in England, Arch. Dis. Child, vol.86, pp.336-338, 2002.

N. S. Crowcroft, C. Stein, P. Duclos, and M. Birmingham, How best to estimate the global burden of pertussis?, Lancet Infect. Dis, vol.3, pp.413-418, 2003.

M. M. Cortese, A. L. Baughman, R. Zhang, P. U. Srivastava, and G. S. Wallace, Pertussis hospitalizations among infants in the United States, Pediatrics, vol.121, pp.484-492, 1993.

C. H. Von-könig, S. Halperin, M. Riffelmann, and N. Guiso, Pertussis of adults and infants, Lancet Infect. Dis, vol.2, pp.744-750, 2002.

L. P. Celentano, M. Massari, D. Paramatti, S. Salmaso, A. E. Tozzi et al., Resurgence of pertussis in Europe, Pediatr. Infect. Dis. J, vol.24, pp.761-765, 2005.

S. W. Roush and T. V. Murphy, Historical comparisons of morbidity and mortality for vaccinepreventable diseases in the United States, JAMA, vol.298, pp.2155-2163, 2007.

Z. Kmietowicz, Pertussis cases rise 10-fold among older children and adults in England and Wales, BMJ, vol.345, p.5008, 2012.

P. Campbell, P. Mcintyre, H. Quinn, L. Hueston, G. L. Gilbert et al., Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia, PLoS One, vol.7, p.35874, 2012.

K. Winter, K. Harriman, J. Zipprich, R. Schechter, J. Talarico et al., California pertussis epidemic, J. Pediatr, vol.161, pp.1091-1096, 2010.

C. Locht, Pertussis: acellular, whole-cell, new vaccines, what to choose?, Expert Rev. Vaccines, vol.15, pp.671-673, 2016.

P. A. Scuffham and P. B. Mcintyre, Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis, Vaccine, vol.22, pp.2953-2964, 2004.

N. Wood, T. Nolan, H. Marshall, P. Richmond, E. Gibbs et al., Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial, JAMA Pediatr, vol.172, pp.1045-1052, 2018.

B. Adkins, C. Leclerc, and S. Marshall-clarke, Neonatal adaptive immunity comes of age, Nat. Rev. Immunol, vol.4, pp.553-564, 2004.

D. B. Lewis, A. Larsen, and C. B. Wilson, Reduced interferon-gamma mRNA levels in human neonates. Evidence for an intrinsic T cell deficiency independent of other genes involved in T cell activation, J. Exp. Med, vol.163, pp.1018-1023, 1986.

T. Forsthuber, H. C. Yip, and P. V. Lehmann, Induction of TH1 and TH2 immunity in neonatal mice, Science, vol.271, pp.1728-1730, 1996.

R. Higgs, S. C. Higgins, P. J. Ross, and K. H. Mills, Immunity to the respiratory pathogen Bordetella pertussis, Mucosal Immunol, vol.5, pp.485-500, 2012.

A. Marchant, T. Goetghebuer, M. O. Ota, I. Wolfe, S. J. Ceesay et al., Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination, J. Immunol, vol.163, pp.2249-2255, 1999.

F. Mascart, V. Verscheure, A. Malfroot, M. Hainaut, D. Piérard et al., Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses, J. Immunol, vol.170, pp.1504-1509, 2003.

G. Amirthalingam, N. Andrews, H. Campbell, S. Ribeiro, E. Kara et al., Effectiveness of maternal pertussis vaccination in England: an observational study, Lancet, vol.384, pp.1521-1528, 2014.

J. A. Englund, E. L. Anderson, G. F. Reed, M. D. Decker, K. M. Edwards et al., The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and wholecell pertussis vaccines combined with diphtheria and tetanus toxoids, Pediatrics, vol.96, pp.580-584, 1995.

S. A. Halperin, J. M. Langley, L. Ye, D. Mackinnon-cameron, M. Elsherif et al., A randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response, Clin. Infect. Dis, vol.67, pp.1063-1071, 2018.

N. Wanlapakorn, K. Maertens, S. Vongpunsawad, J. Peunpa, T. M. Tran et al., Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial, Clin. Infect. Dis, 2019.

M. L. Erb, T. E. Erlanger, and U. Heininger, Child-parent immunization survey: how well are national immunization recommendations accepted by the target groups? Vaccine X 1, p.100013, 2019.

C. Locht, Will we have new pertussis vaccines?, Vaccine, vol.36, pp.5460-5469, 2018.

J. M. Warfel, L. I. Zimmerman, and T. J. Merkel, Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model, Proc. Natl. Acad. Sci. USA, vol.111, pp.787-792, 2014.

H. J. Wearing and P. Rohani, Estimating the duration of pertussis immunity using epidemiological signatures, PLoS Pathog, vol.5, p.1000647, 2009.

A. M. Wendelboe, A. Van-rie, S. Salmaso, and J. A. Englund, Duration of immunity against pertussis after natural infection or vaccination, Pediatr. Infect. Dis. J, vol.24, pp.58-61, 2005.

N. Mielcarek, A. S. Debrie, D. Raze, J. Bertout, C. Rouanet et al., Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough, PLoS Pathog, vol.2, p.65, 2006.

N. Mielcarek, A. S. Debrie, S. Mahieux, and C. Locht, Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice, Clin. Vaccine Immunol, vol.17, pp.317-324, 2010.

H. Kavanagh, C. Noone, E. Cahill, K. English, C. Locht et al., Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergeninduced immunity and prevents allergic pulmonary pathology in a murine model, Clin. Exp. Allergy, vol.40, pp.933-941, 2010.

C. M. Skerry, J. P. Cassidy, K. English, P. Feunou-feunou, C. Locht et al., A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice, Clin. Vaccine Immunol, vol.16, pp.1344-1351, 2009.

P. F. Feunou, J. Bertout, and C. Locht, T-and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis, PLoS One, vol.5, p.10178, 2010.

L. Solans, A. S. Debrie, L. Borkner, N. Aguiló, A. Thiriard et al., IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine, Mucosal Immunol, vol.11, pp.1753-1762, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02398320

C. Locht, J. F. Papin, S. Lecher, A. S. Debrie, M. Thalen et al., Live attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection, J. Infect. Dis, vol.216, pp.117-124, 2017.

R. Thorstensson, B. Trollfors, N. Al-tawil, M. Jahnmatz, J. Bergström et al., A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers, PLoS One, vol.9, p.83449, 2014.

P. F. Feunou, H. Kammoun, A. S. Debrie, N. Mielcarek, and C. Locht, Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1, Vaccine, vol.28, pp.7047-7053, 2010.

C. M. Skerry and B. P. Mahon, A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model, Clin. Vaccine Immunol, vol.18, pp.187-193, 2011.

F. D. Menozzi, R. Mutombo, G. Renauld, C. Gantiez, J. H. Hannah et al., Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis, Infect. Immun, vol.62, pp.769-778, 1994.

R. Antoine, I. Huvent, K. Chemlal, I. Deray, D. Raze et al., The periplasmic binding protein of a tripartite tricarboxylate transporter is involved in signal transduction, J. Mol. Biol, vol.351, pp.799-809, 2005.

A. Poltorak, X. He, I. Smirnova, M. Y. Liu, C. Van-huffel et al., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene, Science, vol.282, pp.2085-2088, 1998.

A. Didierlaurent, I. Ferrero, L. A. Otten, B. Dubois, M. Reinhardt et al., Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response, J. Immunol, vol.172, pp.6922-6930, 2004.

S. Uematsu, M. H. Jang, N. Chevrier, Z. Guo, Y. Kumagai et al., Detection of pathogenic intestinal bacteria by toll-like receptor 5 on intestinal CD11c + lamina propria cells, Nat. Immunol, vol.7, pp.868-874, 2006.

N. Mielcarek, J. Cornette, A. M. Schacht, R. J. Pierce, C. Locht et al., Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen, Infect. Immun, vol.65, pp.544-550, 1997.

A. Imaizumi, Y. Suzuki, S. Ono, H. Sato, and Y. Sato, Heptakis(2,6-O-dimethyl)beta-cyclodextrin: a novel growth stimulant for Bordetella pertussis phase I, J. Clin. Microbiol, vol.17, pp.781-786, 1983.

E. F. Kenny and L. A. O'neill, Signalling adaptors used by toll-like receptors: an update, Cytokine, vol.43, pp.342-349, 2008.

A. Dunne, L. A. Mielke, A. C. Allen, C. E. Sutton, R. Higgs et al., A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine, Mucosal Immunol, vol.8, pp.607-617, 2015.

G. Moreno, A. Errea, L. Van-maele, R. Roberts, H. Léger et al., Toll-like receptor 4 orchestrates neutrophil recruitment into airways during the first hours of Bordetella pertussis infection, Microbes Infect, vol.15, pp.708-718, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00925669

K. Hoshino, O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa et al., Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product, J. Immunol, vol.162, pp.3749-3752, 1999.

T. Koga, T. Nishihara, T. Fujiwara, T. Nisizawa, N. Okahashi et al., Biochemical and immunobiological properties of lipopolysaccharide (LPS) from Bacteroides gingivalis and comparison with LPS from Escherichia coli, Infect. Immun, vol.47, pp.638-647, 1985.

R. F. Bey, F. J. Shade, R. A. Goodnow, and R. C. Johnson, Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis, Am. J. Vet. Res, vol.42, pp.1130-1132, 1981.

V. A. Koeken, A. J. Verrall, M. G. Netea, P. C. Hill, and R. Van-crevel, Trained innate immunity and resistance to Mycobacterium tuberculosis infection, Clin. Microbiol. Infect, vol.DOI, 2019.

P. B. Mann, D. Wolfe, E. Latz, D. Golenbock, A. Preston et al., Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection, Infect. Immun, vol.73, pp.8144-8152, 2005.

P. B. Mann, M. J. Kennett, and E. T. Harvill, Toll-like receptor 4 is critical to innate host defense in a murine model of bordetellosis, J. Infect. Dis, vol.189, pp.833-836, 2004.

H. Kammoun, P. F. Feunou, B. Foligne, A. S. Debrie, D. Raze et al., Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice, Vaccine, vol.30, pp.5864-5870, 2012.

H. A. Banus, R. J. Vandebriel, H. De-ruiter, J. A. Dormans, N. J. Nagelkerke et al., Host genetics of Bordetella pertussis infection in mice: significance of toll-like receptor 4 in genetic susceptibility and pathobiology, Infect. Immun, vol.74, pp.2596-2605, 2006.

A. Errea, G. Moreno, F. Sisti, J. Fernández, M. Rumbo et al., Mucosal innate response stimulation induced by lipopolysaccharide protects against Bordetella pertussis colonization, Med. Microbiol. Immunol. (Berl.), vol.199, pp.103-108, 2010.

S. C. Higgins, E. C. Lavelle, C. Mccann, B. Keogh, E. Mcneela et al., Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology, J. Immunol, vol.171, pp.3119-3127, 2003.

S. C. Higgins, A. G. Jarnicki, E. C. Lavelle, and K. H. Mills, TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells, J. Immunol, vol.177, pp.7980-7989, 2006.

S. Banus, R. W. Bottema, C. L. Siezen, R. J. Vandebriel, J. Reimerink et al., Toll-like receptor 4 polymorphism associated with the response to whole-cell pertussis vaccination in children from the KOALA study, Clin. Vaccine Immunol, vol.14, pp.1377-1380, 2007.

T. G. Kimman, S. Banus, N. Reijmerink, J. Reimerink, F. F. Stelma et al., Association of interacting genes in the toll-like receptor signaling pathway and the antibody response to pertussis vaccination, PLoS One, vol.3, p.3665, 2008.

K. Gröndahl-yli-hannuksela, J. Vuononvirta, A. M. Barkoff, M. Viander, O. Van-der-meeren et al., Gene polymorphism in tolllike receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence, J. Infect. Dis, vol.205, pp.1214-1219, 2012.

N. Maeshima, T. Evans-atkinson, A. M. Hajjar, and R. C. Fernandez, Bordetella pertussis lipid A recognition by toll-like receptor 4 and MD-2 is dependent on distinct charged and uncharged interfaces, J. Biol. Chem, vol.290, pp.13440-13453, 2015.

M. K. Racke, W. Hu, and A. E. Lovett-racke, PTX cruiser: driving autoimmunity via TLR4, Trends Immunol, vol.26, pp.289-291, 2005.

C. Locht, L. Coutte, and N. Mielcarek, The ins and outs of pertussis toxin, FEBS J, vol.278, pp.4668-4682, 2011.

Z. Y. Wang, D. Yang, Q. Chen, C. A. Leifer, D. M. Segal et al., Induction of dendritic cell maturation by pertussis toxin and its B subunit differentially initiate toll-like receptor 4-dependent signal transduction pathways, Exp. Hematol, vol.34, pp.1115-1124, 2006.

N. R. Shah, S. Albitar-nehme, E. Kim, N. Marr, A. Novikov et al., Minor modifications to the phosphate groups and the C39 acyl chain length of lipid A in two Bordetella pertussis strains, BP338 and 18-323, independently affect toll-like receptor 4 protein activation, J. Biol. Chem, vol.288, pp.11751-11760, 2013.

K. R. Balka and D. De-nardo, Understanding early TLR signaling through the Myddosome, J. Leukoc. Biol, vol.105, pp.339-351, 2019.

C. E. Bryant, M. Symmons, and N. J. Gay, Toll-like receptor signalling through macromolecular protein complexes, Mol. Immunol, vol.63, pp.162-165, 2015.

N. J. Bernard, C. M. Finlay, G. M. Tannahill, J. P. Cassidy, L. A. O'neill et al., A critical role for the TLR signaling adapter Mal in alveolar macrophage-mediated protection against Bordetella pertussis, Mucosal Immunol, vol.8, pp.982-992, 2015.

N. J. Bernard and L. A. O'neill, Mal, more than a bridge to MyD88, IUBMB Life, vol.65, pp.777-786, 2013.

G. L. Foster, T. A. Barr, A. J. Grant, T. J. Mckinley, C. E. Bryant et al., Virulent Salmonella enterica infections can be exacerbated by concomitant infection of the host with a live attenuated S. enterica vaccine via toll-like receptor 4-dependent interleukin-10 production with the involvement of both TRIF and MyD88, Immunology, vol.124, pp.469-479, 2008.

S. C. De-greeff, H. E. De-melker, P. G. Van-gageldonk, J. F. Schellekens, F. R. Van-der-klis et al., Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis, PLoS One, vol.5, p.14183, 2010.

H. E. De-melker, F. G. Versteegh, J. F. Schellekens, P. F. Teunis, and M. Kretzschmar, The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys, J. Infect, vol.53, pp.106-113, 2006.

I. Ben-fraj, M. Zghal, M. Hsairi, A. Kechrid, and H. Smaoui, Seroprevalence of Bordetella pertussis toxin antibodies in children and adolescents in Tunis, Tunisia. Epidemiol. Infect, vol.147, p.199, 2019.

R. Palazzo, M. Carollo, G. Fedele, C. Rizzo, M. C. Rota et al., Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data, J. Med. Microbiol, vol.65, pp.649-657, 2016.

Q. Zhang, Z. Yin, Y. Li, H. Luo, Z. Shao et al., Prevalence of asymptomatic Bordetella pertussis and Bordetella parapertussis infections among school children in China as determined by pooled real-time PCR: a cross-sectional study, Scand. J. Infect. Dis, vol.46, pp.280-287, 2014.

S. Cauchi and C. Locht, Non-specific effects of live attenuated pertussis vaccine against heterologous infectious and inflammatory diseases, Front. Immunol, vol.9, p.2872, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02346767

R. Li, A. Lim, M. C. Phoon, T. Narasaraju, J. K. Ng et al., Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm, J. Virol, vol.84, pp.7105-7113, 2010.

R. Li, C. Cheng, S. Z. Chong, A. R. Lim, Y. F. Goh et al., Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models, Allergy, vol.67, pp.1250-1258, 2012.